Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells
- PMID: 15090456
- DOI: 10.1182/blood-2003-10-3469
Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells
Abstract
Immunotherapeutic approaches to limit cytomegalovirus (CMV) morbidity and mortality after hematopoietic stem cell transplants (HSCTs) are currently under investigation as alternatives to antiviral drugs. In this context, we have inserted full-length and ubiquitin-modified CMV phosphoprotein 65 (pp65), phosphoprotein 150 (pp150), and immediate early protein 1 (IE1) immunodominant antigens into the virulent Western Reserve strain of vaccinia virus (VV) and the highly attenuated strain, modified vaccinia Ankara (MVA). Recombinant (r) VV or rMVA stimulated vigorous expansion of CMV-specific CD8+ T cells in CMV-positive donor peripheral blood mononuclear cells (PBMCs), which showed minimal alloreactivity and high levels of HLA tetramer binding, cytokine production, and cytotoxicity. Ubiquitinated antigens had a profound effect when expressed in VV. Single antigen rMVA expressing pp65 or IE1, either ubiquitin-modified or native, stimulated both cytotoxic T lymphocyte (CTL) populations to be expanded up to 500-fold in a 60-mL blood draw from the same donor. This result demonstrates the clinical feasibility of simultaneously amplifying multiple CMV-CTL populations. Transgenic HLA A2.1 (HHD II) mice, immunized with the same rMVA as used with human PBMCs, produced a robust cytotoxic response to both CMV pp65 and IE1. The specificity of the vigorous immunologic response to rMVA, both in vitro and in vivo, makes them candidates for clinical evaluation in the context of adoptive immunotherapy for hematopoietic stem cell transplant (HSCT) recipients or donor vaccination.
Similar articles
-
Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.Vaccine. 2007 Jan 22;25(6):1132-41. doi: 10.1016/j.vaccine.2006.09.067. Epub 2006 Oct 6. Vaccine. 2007. PMID: 17049414 Free PMC article.
-
In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.Exp Hematol. 2006 Apr;34(4):497-507. doi: 10.1016/j.exphem.2005.12.018. Exp Hematol. 2006. PMID: 16569596
-
Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.J Clin Virol. 2006 Mar;35(3):324-31. doi: 10.1016/j.jcv.2005.09.018. Epub 2006 Jan 4. J Clin Virol. 2006. PMID: 16388983
-
Characterization of host immunity to cytomegalovirus pp150 (UL32).Hum Immunol. 2005 Feb;66(2):116-26. doi: 10.1016/j.humimm.2004.10.008. Hum Immunol. 2005. PMID: 15694996
-
Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.Med Microbiol Immunol. 2016 Dec;205(6):549-561. doi: 10.1007/s00430-016-0471-0. Epub 2016 Aug 18. Med Microbiol Immunol. 2016. PMID: 27539576 Review.
Cited by
-
Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.Vaccine. 2007 Jan 22;25(6):1132-41. doi: 10.1016/j.vaccine.2006.09.067. Epub 2006 Oct 6. Vaccine. 2007. PMID: 17049414 Free PMC article.
-
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.Cancer Immunol Immunother. 2011 Jan;60(1):99-109. doi: 10.1007/s00262-010-0923-0. Epub 2010 Oct 20. Cancer Immunol Immunother. 2011. PMID: 20960189 Free PMC article.
-
MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.Blood. 2017 Jan 5;129(1):114-125. doi: 10.1182/blood-2016-07-729756. Epub 2016 Oct 19. Blood. 2017. PMID: 27760761 Free PMC article. Clinical Trial.
-
A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.Virology. 2008 Aug 1;377(2):379-90. doi: 10.1016/j.virol.2008.04.034. Epub 2008 Jun 5. Virology. 2008. PMID: 18538366 Free PMC article.
-
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?Curr Opin Biotechnol. 2004 Dec;15(6):506-12. doi: 10.1016/j.copbio.2004.09.001. Curr Opin Biotechnol. 2004. PMID: 15560976 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials